Coming to a consensus: the development of a new mRNA vaccine
Original story from the University of Pittsburgh (PA, USA).
New mRNA vaccine is more effective and less costly to develop.
A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, according to a study by researchers at University of Pittsburgh School of Public Health and the Pennsylvania State University (PA, USA).
Though highly effective at inducing an immune response, current mRNA vaccines, such as those used to prevent COVID-19, present two significant challenges: the high amount of mRNA needed to produce them and the constantly evolving nature of the pathogen.
“The virus changes, moving the goal post, and updating the vaccine takes some time,” commented senior author Suresh Kuchipudi, chair of Infectious Diseases and Microbiology at Pitt Public Health.
New blood-based method for detecting rare diseases
A single, untargeted proteomics test for rare genetic diseases has been developed.
To address these challenges, the researchers created a proof-of-concept COVID-19 vaccine using what’s known as a ‘trans-amplifying’ mRNA platform. In this approach, the mRNA is separated into two fragments – the antigen sequence and the replicase sequence – the latter of which can be produced in advance, saving crucial time in the event a new vaccine must be developed urgently and produced at scale.
Additionally, the researchers analyzed the spike-protein sequences of all known variants of the SARS-CoV-2 for commonalities, rendering what’s known as a ‘consensus spike protein’ as the basis for the vaccine’s antigen.
In mice, the vaccine induced a robust immune response against many strains of SARS-CoV-2.
“This has the potential for more lasting immunity that would not require updating, because the vaccine has the potential to provide broad protection,” explained Kuchipudi. “Additionally, this format requires an mRNA dose 40 times less than conventional vaccines, so this new approach significantly reduces the overall cost of the vaccine.”
The lessons learned from this study could inform more efficient vaccine development for other constantly evolving RNA viruses with pandemic potential. Kuchipudi concluded, “We hope to apply the principles of this lower-cost, broad-protection antigen design to pressing challenges like bird flu.”
This article has been republished from the following materials. Material may have been edited for length and house style. For further information, please contact the cited source. Our press release publishing policy can be accessed here.
